What is the recommended drug therapy regimen for peripheral arterial disease?

General Drug Therapy for PAD

All patients with symptomatic PAD should receive single antiplatelet therapy (aspirin 75-100 mg daily OR clopidogrel 75 mg daily) combined with high-intensity statin therapy to reduce cardiovascular death, MI, and stroke. 1

Core Medical Therapy Components

Antiplatelet Therapy

For symptomatic PAD patients:

• First-line: Clopidogrel 75 mg daily is preferred over aspirin based on superior MACE reduction 1, 2
• Alternative: Aspirin 75-325 mg daily is acceptable 3, 1
• Both reduce risk of MI, stroke, and vascular death with Class I, Level A evidence 4

For asymptomatic PAD (ABI ≤0.90):

• Antiplatelet therapy is reasonable but less established (Class IIa, Level C) 4, 3
• Consider if patient has diabetes or other high-risk features 5

Enhanced antithrombotic regimens:

• Rivaroxaban 2.5 mg twice daily + aspirin 100 mg daily is highly effective for reducing both MACE and major adverse limb events (MALE) in symptomatic PAD 1, 5
• This combination should be considered in patients with high ischemic risk and non-high bleeding risk 5
• Particularly beneficial after revascularization procedures 6, 1
• Critical caveat: Increases major bleeding risk - avoid in patients with prior hemorrhagic stroke, recent stroke (<1 month), eGFR <15 mL/min, or strong CYP3A4 interactions 6

Dual antiplatelet therapy (aspirin + clopidogrel):

• Benefit uncertain for stable PAD without recent revascularization (Class IIb) 1
• May be considered for 1-6 months after endovascular revascularization 1
• Reserved for high cardiovascular risk patients not at increased bleeding risk 4

What NOT to use:

• Warfarin plus antiplatelet therapy is contraindicated - no benefit and potentially harmful due to increased bleeding (Class III) 4
• Vorapaxar has uncertain benefit and increases bleeding 3, 1

Lipid Management

Statin therapy is mandatory for ALL PAD patients (Class I, Level A) 3, 1

• High-intensity statin therapy reduces cardiovascular events and mortality
• Target aggressive LDL reduction regardless of baseline lipid levels
• This is non-negotiable guideline-directed therapy

Symptom Management for Claudication

Cilostazol 100 mg twice daily:

• First-line pharmacotherapy for lifestyle-limiting claudication (Class I, Level A) 4
• Improves walking distance and symptoms
• Absolute contraindication: Heart failure of any severity
• Common side effects: headache, diarrhea, dizziness, palpitations (20% discontinuation rate) 3
• Should be trialed in all patients with lifestyle-limiting claudication who lack heart failure 4

Pentoxifylline 400 mg three times daily:

• Second-line alternative only if cilostazol not tolerated (Class IIb) 4
• Clinical effectiveness is marginal and not well established
• Generally not recommended given limited efficacy

Avoid ineffective therapies:

• L-arginine, propionyl-L-carnitine, ginkgo biloba - effectiveness not established 4
• Chelation therapy (EDTA) - not indicated and may be harmful 4

Hypertension Management

• Antihypertensive therapy reduces MI, stroke, heart failure, and cardiovascular death (Class I, Level A) 3
• ACE inhibitors or ARBs are preferred - effective for reducing cardiovascular ischemic events in PAD (Class IIa, Level A) 3

Diabetes Management

• Coordinate glycemic control between healthcare team members
• Target HbA1c <7% to reduce microvascular complications 4
• Glycemic control particularly beneficial in critical limb ischemia for limb-related outcomes 3

Smoking Cessation

Mandatory intervention at every visit (Class I, Level A) 4, 3

• Assist with developing quit plan including pharmacotherapy
• Offer varenicline, bupropion, and/or nicotine replacement therapy 4
• Refer to smoking cessation programs

Supervised Exercise Therapy

Supervised exercise training is Class I recommendation 4

• Minimum 30-45 minutes per session
• At least 3 times per week
• Minimum 12 weeks duration
• Should be initial treatment for intermittent claudication before considering revascularization
• Unsupervised programs have uncertain effectiveness (Class IIb) 4

Post-Revascularization Therapy

After endovascular or surgical revascularization:

• Preferred: Rivaroxaban 2.5 mg twice daily + aspirin (Class I, Level A) 1
• Alternative: Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for 1-6 months 1
• After prosthetic bypass: Consider dual antiplatelet therapy for at least 1 month 1

Common Pitfalls to Avoid

1. Underutilization of medical therapy: PAD patients receive less guideline-directed therapy than CAD patients despite similar or higher risk 3
2. Forgetting cilostazol contraindication: Never prescribe in any degree of heart failure
3. Inappropriate warfarin use: Do not add warfarin to antiplatelet therapy without another indication (atrial fibrillation, mechanical valve)
4. Neglecting statin therapy: All PAD patients need statins regardless of lipid levels
5. Skipping exercise therapy: Always recommend supervised exercise before considering revascularization for claudication

Algorithm Summary

For ALL symptomatic PAD patients:

1. Single antiplatelet (clopidogrel preferred, or aspirin)
2. High-intensity statin
3. Blood pressure control (prefer ACE-I/ARB)
4. Smoking cessation with pharmacotherapy
5. Diabetes management if applicable

For lifestyle-limiting claudication ADD:

• Supervised exercise program (mandatory first step)
• Cilostazol 100 mg BID (if no heart failure)

For high ischemic risk/post-revascularization CONSIDER:

• Rivaroxaban 2.5 mg BID + aspirin (if low bleeding risk)